Importantly, this positive effect was not only NPM1 mutation-dependent, but also IDH2 mutation-specific: NPM1+/IDH2-R140+ NK-AML patients had significantly better outcomes compared to those with NPM1+/IDH2-R140− (OS: 47% and 27% for NPM1+/IDH2-R140+ vs NPM1+/IDH2-R140−, p = 0.007) after censoring at alloHSCT (Supplemental Fig. S1B). This evidence concerns the gene NPM1 and acute myeloid leukemia.